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ABSTRACT 
BACKGROUND: 
Oral squamous cell  carcinoma (OSCC), represents over 90% of 
malignancies of the oral cavity .
 
Despite the advances in diagnosis and 
therapy, OSCC continues to have a shorter survival rate. Verrucous 
carcinoma (VC)  of the oral  cavity is a low grade variant of  OSCC. 
The study of cell  proliferation is important for assessing the tumor 
behaviour, prognosis and patient survival of both these tumours. As 
literature search did not reveal sufficient studies of 
immunohistochemical expression of Cyclin D1 and Mini Chromosome 
Maintainance 2 (MCM2) in OSCC and VC, the present study was done 
to evaluate the  expression of these two cell  proliferation biomarkers  
in  Oral  Squamous cell  carcinoma and  Verrucous carcinoma.    
AIM: 
 To evaluate the immunohistochemical expression of MCM 2 and  
Cyclin D1 in oral squamous cell carcinoma and   verrucous  carcinoma.  
MATERIALS AND METHODS: 
This immunohistochemical  study was conducted on the archives 
retrieved formalin fixed, paraffin embedded t issue sections from the 
Department of Oral and Maxillofacial Pathology, Adhiparasakthi  
Dental College and Hospital,  Melmaruvathur.  The study group included 
20 cases of histopathologically diagnosed Oral Squamous Cell  
Carcinoma (10 cases of well  differentiated squamous cell  carcinoma, 
10 cases of Moderately differentiated Squamous Cell Carcinoma) and 
10 cases of histopathologically di agnosed verrucous carcinoma. 
Control group included 10 biopsies from the normal buccal mucosa 
adjacent to the site of surgery during the surgical removal of third 
molars in patients. All samples were evaluated for the expression of 
Cyclin D1 and MCM 2 using standard immunohistochemistry  
procedure.  
The present study involved both quali tative and quantitat ive 
analysis. Qualitative analysis was done by evaluation of intensity of 
staining and area of staining. Quantitative analysis was done by 
calculating the percentage of positively stained cells and assessing the 
Labell ing Index. Data obtained was subjected to statistical analysis 
using SPSS statistical package (version 19 .0).  
RESULTS 
 On evaluating and comparing Cyclin D1 and MCM 2 intensity 
and area of staining between the groups, statistically significant values 
(p<0.05) were obtained using Kruskall Wallis’ ANOVA. Comparison of 
LI of Cyclin D1 and MCM 2 in normal mucosa, OSCC and VC 
statistically significant results (p<0.05) were obtained using Mann 
Whitney U test . Mean LI of MCM2 was found to be significantly 
higher than mean LI of cyclin D1 in all the study groups.  
CONCLUSION 
 From the present study we conclude that  MCM2 has the  
potential to serve as a novel cell proliferation biomarker in OSCC and 
VC as compared to Cyclin D1.  
Key Words: Oral squamous cell carcinoma, Verrucous carcinoma, 
Cyclin D1, MCM2, cell proliferation.  
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INTRODUCTION 
 
Oral squamous cell carcinomas (OSCC)   belonging to a  larger 
subgroup of tumours termed head and neck squamous cell  carcinomas 
(HNSCC)   represents over 90% of malignant oral  neoplasms
1
.  
According to the International Agency for Research on Cancer, the 
incidence rate of oral cancer in India is  12.6 per 100,000 people  when 
compared to United States and the Middle East  which is 10 per 
1,00,000 and less than 2 per 1,00,000 respectively
2
.
 
The high incidence 
of OSCC in India has been attributed to a variety of etiological  factors 
such as smoking,  smokeless tobacco chewing, alcohol consumption,  
spicy food intake and human papillomavirus (HPV) infections
1
.  These 
factors may act individually or synergist ically in oral carcinogenesis , a 
multistage process, that  involves precancerous lesions, invasion and 
metastasis
3
.   
 
Verrucous carcinoma (VC), a rare tumor first described by 
Ackerman
4
 is  a low grade variant of OSCC and is being considered as a 
separate clinicopathologic entity dist inct from OSCC because of its 
unique biologic behaviour and  slow growing nature . VC has a limited 
propensity to metastasize,  hence with  a better prognosis than OSCC
5
.   
Few studies reveal that  some foci of SCC may be observed in 20% of  
VC cases, making it a hybrid tumor and conferring a metastatic 
potential to it
6
.  
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Numerous studies have been done with a prime objective of 
understanding the biology, diagnosis,  prognosis, and management of 
OSCC and VC. Despite considerable advances in the  diagnostic and 
therapeutic techniques,  OSCC continues to pres ent a poor prognosis 
with a two to five year survival rate of 50-60% depending upon the 
stage of disease and site affected
7
.
 
Because the prognosis of the 
patients decrease with increasing tumor stage,  it  is  of great importance 
to detect the tumor as early as possible.  If    OSCC is diagnosed at an 
early stage (T1N0) survival rate of upto  80% is noted but in the later 
stages(T3-T4),  it   fal ls to  about  20–30%8 .  
 
Recent studies have clarified that a variety of molecular events  
at cellular levels play extremely important roles in  not only tumor 
development but also tumor progression
9
.  Studies have supported that  
oral  carcinogenesis emerge from the accumulation of genetic changes 
and epigenetic anomalies in the expression of multiple genes
1 0
.  
Consequently,  special attention has turned to wards molecular 
biomarkers which are biochemical components that can define 
molecular and cellular  alterations in both normal cell s and those 
associated with malignant transformation
1 1
.  
 
Several  biomarkers have been used in order to provide additional 
information about these tumors, including the inactivation of tumor 
suppressor genes, angiogenesis, apoptosis and cell  proliferation 
markers
1 1
.  The molecular markers of interest are those involved in cell 
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cycle regulation of tumor cells since ca rcinoma is caused by 
uncontrolled proliferation of cells
1 2
.  Assessment of cell proliferation 
activity in tumors has become a common tool used by histopathologists  
in order to provide useful information for diagnosis, clinical behavior,  
and therapy of tumours
1 3
.  
 
The commonly used cell proliferation markers in OSCC include 
Ki-67, PCNA (Proliferating Cell Nuclear Antigen) ,  Geminin, Cyclin 
D1, and Cyclin B1
1 1
.  Indeed, the strongest connection bet ween Cyclins 
and oncogenesis have been reported in studies conducted in OSCC
1 4
.  
Recent studies have proposed  that Minichromosome Maintainance 
(MCM) proteins could also be sensitive proliferation markers and  
serve as novel biomarkers to determine the  diagnosis and prognosis of 
various premalignant and malignant lesions
1 5
.   
 
The orderly progression of the cells through the various phases 
of cell cycle is controlled by a series of proteins  called “Cyclins,” 
which exert  their effect  by binding and activating the Cyclin -
Dependent Kinases (CDK)
1 6
.  Both CDKs and Cyclins are posit ive 
regulators of cell cycle
1 7
.  
 
Among the cyclins, Cyclin D1 appears to be 
important in the G1 phase which is the only phase where the 
extracellular stimuli  like growth factors can have an effect  on the cell  
cycle
1 6
.  Amplification and overexpression of Cyclin D1 have  been 
reported in head and neck, oral , laryngeal and nasopharyngeal 
carcinoma
1 8
.  
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The minichromosome maintenance (MCM) protei ns form a family 
of molecules that  are essential   in DNA synthesis and for the S -phase 
of cell  cycle init iat ion 
1 9
.  MCM proteins form a heterohexameric ring 
of MCM2–MCM7 complexes that  act  as replicative DNA helicase 2 0  
and ensure that DNA replicates only once per mitotic cycle 
2 1
.Because 
of its expression in the early G1 phase, few studies have demonstrated 
that  MCM proteins can be used as proliferation markers for determing 
the tumour behaviour
2 0  
 and MCM-2 protein can be used not only to 
estimate the proliferative index, but also as a prognostic factor for the 
survival rate of patients with OSCC
1 1
.  
 
Therefore, detection of MCM2 and Cyclin D1 can be used to 
distinguish cells that  exhibit aberrant cel l  proliferat ion activity   
promoting tumour cells  toward more advanced stages  causing invasion  
to deeper t issues and metastasis to regional lymph nodes
2 2 , 2 3
 Though 
few studies have been carried out to detect  the  expression of   Cyclin 
D1 and MCM2 in different grades of  OSCC
2 4
,  literature search reveal 
very few studies on the expression of these markers in verrucous 
carcinoma. With this background, the present study  has been 
undertaken to evaluate the  immunohistochemical expression of MCM2 
and cyclin D1 in well and moderately differentiated oral squamous cell  
carcinoma and verrucous carcinoma.  
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AIM & OBJECTIVES 
 
Aim: 
To  evaluate  the immunohistochemical expression of Cyclin D1 
and  MCM 2 in oral  squamous cell  carcinoma and verrucous  
carcinoma.  
 
Objectives:  
1.  To determine and compare the intensities of expression of Cyclin  
D1 in oral Well  differentiated squamous cell carcinoma, 
Moderately differentiated  squamous cell carcinoma, Verrucous 
carcinoma and Normal mucosa  
2.  To determine and compare  the area of staining of Cyclin D1  in 
oral   Well differentiated squamous cell  carc inoma, Moderately 
differentiated  squamous cell carcinoma, Verrucous carcinoma 
and Normal mucosa  
3.  To determine and compare the intensities of expression of MCM 
2 in oral Well  differentiated squamous cell  carcinoma, 
Moderately differentiated squamous cell ca rcinoma, Verrucous 
carcinoma and Normal mucosa  
4.  To determine and compare the area of staining of  MCM 2 in oral 
Well differentiated squamous cell carcinoma, Moderately 
differentiated  squamous cell carcinoma , Verrucous carcinoma 
and Normal mucosa  
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5.  To compare the intensities of expression of Cyclin D1 and 
MCM2 in Well differentiated squamous cell  carcinoma,  
Moderately differentiated squamous cell carcinoma and 
Verrucous carcinoma.  
6.  To compare the area of staining of Cyclin D1 and MCM2 in  well  
differentiated squamous cell carcinoma, Moderately 
differentiated squamous cell carcinoma and Verrucous 
carcinoma.  
7.  To determine and compare the Labelling Index (LI) of Cyclin D1 
in oral Squamous cell carcinoma, Verrucous carcinoma and 
Normal mucosa.  
8.  To determine and compare the Labelling Index (LI) of MCM 2 in 
oral  Squamous cell  carcinoma, Verrucous carcinoma and Normal 
mucosa.  
9.  To compare the LI of Cyclin D1 and MCM2 in oral  Squamous 
cell carcinoma, Verrucous carcinoma and Normal mucosa.  
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REVIEW OF LITERATURE 
 
GENERAL REVIEW 
CELL PROLIFERATION MARKERS IN ORAL SQUAMOUS CELL 
CARCINOMA 
 Molecular alterations that cause abnormal biological behavior of 
cancer cells especially uncontrolled cell proliferation  are based on 
aberrations of cell cycle regulation
1 1
.
 
 A normal cell  cycle consists of 
resting phase (G0), followed by  the interphase which starts with G1 
(Gap 1) where the cell increases in size
2 5 ,2 6
.  This is followed by the S-
phase (synthesis) where the DNA replication occur . Then, the cell  
enters into G2 (Gap 2) phase which ensures that  the cel l is  ready for 
mitosis (Figure 1). Mitotic phase (M phase) is composed of two major 
events, nuclear division (Karyokinesis) and cytoplasmic division 
(Cytokinesis) and daughter cells are formed .  
 
Figure 1: Cell  Cycle showing interphase and mitosis  
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 There are various check points present in the cell cycle,  the 
important being G1 /S and G2/ M, both of  these ensure that each phase 
is completed before the next one is initiated
1 6
 .  Restriction Point i s  no 
return point  in the  late G1 phase  because once the cell crosses this, i t  
is committed to another round of cell cycle
1 6
.  Cell cycle progression is 
regulated by factors like  Cyclins, CDKs, inhibitory enzymes, the 
retinoblastoma (Rb) protein, p21, p27 and p53
2 7
.  After passing the 
restriction point late in G1, a cell will ignore exogenous signals and 
will  enter DNA synthesis.  After DNA synthesis,  major intracellular 
insults, such as genomic damage or metabolic disruption can  stop cell  
cycle progression, and the cells will be arres ted at  other checkpoints in 
S, G2, or M phase
1 1
.  
 
 The study of cell  proliferation is important for the assessment of 
tumor behavior, and this parameter has been  linked with the 
assessment of prognosis,  patient survival and  tumor staging. Various 
techniques  for the measurement of cell proliferation rate includes flow 
cytometry,  which analyzes the percentage of cells in specific phases of 
the cell  cycle, immunohistochemistry,  genomics and proteomics. The 
cell proliferation markers can be grouped into three main categories
1 1
:   
1.  Growth fraction markers,  such as Ki67  
2.  Cycle-specific markers (e.g., PCNA, cyclins )  
3.  Cell cycle t ime markers (e.g. , AgNOR - Argyrophilic Nucleolar  
                                                                    Organiser Region)  
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 New cell proliferation markers are Minichromosome maintenance 
proteins (MCM) and geminin which helps in regulating cellular 
differentiation and proliferation. Both have been used as effective 
markers for early detection of cancer, especially in samples with 
suspected malignant epithelial  tumor
2 8
.  
 
CYCLIN D1  
 Growth factors activates the regulatory proteins that   control  the 
transition through G1 phase of cell  cycle
2 9
.  Retinoblastoma (Rb) 
protein and E2F factor act  as mediato rs of the G1 restriction point.  
Phosphorylation of Rb is carried out by cyclin/ cyclin -dependent kinase  
(CDK) complex which  is a heterodimeric complex  composed of a 
catalytic subunit,  the CDK and a regulatory subunit  called a 
cyclin
3 0
.The CDKs are expressed constitutively during the cell  cycle in  
an inactive form, and require cyclins,  which are synthesized during 
specific phases of cell cycle to bind with them and activate them
1 6
.   
 
 Over 30 Cyclin sequences have been identified and eight major 
classes of mammalian cyclins have been isolated and  within some 
classes,  a number of subclasses exist.  So there are at least  11 cyclins 
which attain peak activity during the phases of cell  cycle.  CyclinD1 -3, 
Cyclin E bind with CDK 4/6 and CDK 2 respectively, and regulate 
transition from G1 to S phase,  whereas Cyclins A, B bind to CDK2 and 
CDK1 respectively and are most active during S and G2 phases where 
they regulate transit ion to the mitotic phase of the cell  cycle
 
(Figure 
2)
3 0
.   
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Figure 2: Cyclins and CDK substrates in various phases of  cell 
cycle
3 1
.  
 
 Among the cyclins,  Cyclin D1, a 45 kDa  (Kilodalton), 295 amino 
acid protein encoded by CCND1 gene located at  chromosome 11q13 
and   reported with various other names like PRAD1 and  Bcl-1  is an 
important cyclin in the G1-S transition
1 6
.  Cyclin D1 was ﬁrst  isolated 
as PRAD1 oncogene clonally rearranged and overexpressed in 
parathyroid adenomas
1 7
.  Cyclin D1 protein binds and  activates CDK4 
and CDK6 which leads to phosphorylation of re tinoblastoma protein 
that results in the release of transcriptional activator E2F, leading to 
transcription and activation of proteins associated with passage through 
the G1 checkpoint thus facilitating  progression into the S phase
1 6
.  
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The D-type cyclin dependent kinase performs two functions crucial for 
passage through the G1 phase restriction point .  
 
  The first  function is catalytic and involves the phosphorylation -
dependent inactivation of the Retinoblastoma protein (Rb).  Rb 
phosphorylation results in the release of E2F complexes from 
Rb-dependent repression and  the newly released E2F complexes 
are potent transcriptional activators of genes whose products 
regulate both the G1/S transition and S -phase such as cyclin E.  
   The second function involves the incorporation of members of 
the Cip/Kip family of CDK inhibitory proteins into the cyclin 
D1/CDK4 complex and facilitates the activation of cyclin 
E/CDK2 complexes thereby promoting entry into the DNA  
synthetic phase of the cell division cycle.  
 
 The binding of Cip/Kip proteins  facilitates both assembly of the 
cyclin D1 with CDK4 and ensure that nuclear localization occurs by 
inhibit ion of cyclin D1 nuclear export  in the G1phase of the cell  
cycle
1 6 ,3 0
.  
 
 Due to their crucial role in cell cycle regulation, D-type Cyclin 
have attracted considerable attention with regard to the involvement in 
oncogenesis. Overexpression of Cyclin D1 leads to shortening of the 
G1 phase and reduced dependency on growth factors
1 7
,  hence  resulting 
in abnormal cell  proliferation that  in turn might favor the occurrence of 
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additional genetic lesions. This leads to disturbance in the normal cell 
cycle control  and mitogenic signalling pathways increasing the cell  
transformation and tumourogenecity
9
.
 
This overexpression can be 
detected by immunohistochemical staining by using anti–cyclin D1 
antibody
1 7
.  
 
 Over expression of Cyclin D1 is thought to provide the tumour 
cells with a selective growth advantage. Various factors  responsible for  
overexpression of Cyclin D1 are:  
 Gene amplification at 11q13.  
 Chromosomal rearrangements and translocations (PRAD1, Bcl -1)  
 Upregulation of gene transcription  and post transcriptional 
mechanisms .  
 Post translational stabilization of Cyclin D1 -GSK3β   (Glycogen 
Synthase Kinase 3 beta)                                          
  Retrovirus insert ion .  
 Alteration in synthesis or stability of Cyclin D1 protein 1 7 .  
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MINI CHROMOSOME MAINTAINANCE-2 ( MCM2)  
 Minichromosome Maintenance proteins (MCM) were first  
reported by Maine in 1984 in an attempt to identify factors that  
originate DNA replication
3 2
.  Up to 10 MCM proteins have been 
discovered so far. MCM1 is a transcription factor;  MCM2 -7 proteins  
are best known among this family and are critical components of  the 
replication init iation complex which initiates synthesis of DNA in 
eukaryotes.  MCM10 is a ring shaped hexamer which physically links 
Helicase to DNA polymerase during DNA replication. MCM8 has a role 
in mitosis,  while the role of MCM9 have  not been elucidated 
completely.  Several  studies have shown that MCM proteins remain 
stable during cell cycle while their amount decreases significantly 
during differentiation. This is because the pre -replication complex is 
present throughout the cell cycle. This prop erty makes these proteins  
suitable as proliferation markers
3 2
.  
 
 Minichromosome maintenance proteins are essential  factors for 
replication of DNA which were initially identified in Saccharomyces 
cerevisiae.  Origin recognition complex (ORC) is a protein com plex 
with the ability of binding to the origins of replication and forming a 
landing pad for the replication  factors Cdc6 (Cell division cycle 6 
protein) and Cdt1 (Chromatin licensing and DNA replication factor 1) 
(figure 3). At this time, MCMs (MCM2-7) are recruited to the 
chromatin. So, the pre-replication complex (pre-RC) is formed which 
allows S-phase to be initiated. After S -phase entry,  this complex is 
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disassembled. MCM proteins and Cdc6 leave the chromatin following 
the increased activity of cyclin A-CDK2 (cyclin-dependent kinase2).  
Cdc6 is carried to the cytoplasm and Cdt1 is proteolysed. Any Cdt1 
that has escaped proteolysis will bind to geminin
3 3
.  The nuclear 
localization of the MCM 2-7 complex is regulated by the CDKs. So 
MCM 2-7 are imported into the nucleus when CDK activity is low in 
early G1 and exported from the nucleus during S phase when CDK 
activity is high
3 4
.  As cells exit mitosis, these newly synthesized MCM 
proteins accumulate in the nucleus (early G1 phase) and assemble into 
pre-replicative complexes
3 4 ,3 5
.  
 
 
Figure 3-   MCM proteins and ORC complex.Adapted from 
Marcos Malumbres, in Abeloff's Clinical Oncology (Fifth 
Edition),2014
3 5
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 Minichromosome maintenance-2 (MCM-2) proteins regulates cell  
differentiation and cell proliferation. According to molecular studies, 
MCM-2 proteins identify both cycling cells and non -cycling cells with 
proliferative potential
3 6
.  MCM2, forms a hexameric pre -replication 
complex (pre-RC) with other MCM proteins 3 -7, and attaches to origin 
recognition complex (ORC) in association with Cdc6, which acts as a 
recruitment factor . MCM2 encodes a protein of 890 amino acids, and is 
homologous with MCM3
3 2
.  
 
 When cells exit mitosis Mcm-2 accumulates in the nucleus (early 
G1 phase) and form the pre-replicative complexes with Cdc6,Cdt1, 
Cdc45 allowing CDK activated init iation of DNA synthesis during the 
subsequent phases thus licensing the cells to proliferate
3 2
.
 
 Antibodies 
against MCM-2 identify more cells in tissues in comparison with other 
proliferations markers such as Ki67. Many studies have shown 
overexpression of MCM-2 expression in carcinoma of kidney, colon, 
and larynx. Furthermore, recent studies conducted on precancerous and 
malignant lesions  of oral cavity,  and salivary gland tumou rs showed 
high expression of MCM-2
3 2
.  
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CYCLIN D1 EXPRESSION IN ORAL SQUAMOUS CELL 
CARCINOMA  AND VERRUCOUS CARCINOMA  
Ampliﬁcation of the CCND1 gene is the main o ncogenic mechanism 
underlying cyclin D1 overexpression in OSCC  but  the alteration of 
pathways frequently involved in human carcinogenesis (MAPK, Wnt,  
NF-κβ ) can also transcriptionally activate  the CCND1 gene by 
increasing cyclin D1 expression
3 7 ,3 8
.  These can cause the development 
of larger OSCCs and a higher risk of lymph node involvement
3 7
.  
 
 Satoru Shintan et al.,(2001)3 9  evaluated the relationship 
between cyclin D1 expression levels and radiosensitivity in nine 
oral  SCC cell  lines  and 41 clinical patients with oral  SCC who 
underwent preoperative radiation therapy and found that the  
expression of cyclin D1 varied  and the magnitude of the cyclin  
D1expression correlated with increased tumor radiosensitivity.  
Significant association between the response to preoperative 
radiation therapy and cyclin D1 overexpression was also 
observed in the oral  SCC patients who were treated with 
preoperative radiation therapy. Their results suggested that  
cyclin D1 expression levels correlated with radiosensitivity and 
could be used to predict  the effect iveness of radiation therapy on 
oral SCC. 
 J. Alan Diehl (2002)4 0   reviewed the role of cyclin D1 as a 
mitogenic sensor for the cell  cycle machine and its  role as 
cellular oncogene. He stated that Mitogen -dependent activation 
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of the cyclin D1 kinase occurs through increased transcription, 
protein accumulation, cyclin/CDK assembly, reduced cyclin 
proteolysis, and decreased nuclear export  and the disturbances of 
which provides the  cells with a dist inctive growth advantage 
over their normal counterparts and represents an early event in 
neoplasia. The author also suggested that  removal of proteins 
necessary for the proliferation of tumor cells through targeted 
degradation or subcellular sequestration or both in combination 
with kinase inhibitors might serve as an effective combinatorial 
therapy for certain malignancies.  
 Adriana da Costa Nevus et al . , (2004)4 1  correlated  expression 
of cyclin D1 with the expression of p21 in 28 cases of oral  
squamous cell  carcinoma (OSCC ). No correlation was found 
between the mean numbers of cyclin D1 positive nuclei and p21  
positive nuclei and the histological scores of malignancy.  
However,  the marked expression of cyclin D1 in high -grade 
tumors  supported  its role in proliferative activity.   
 Masayuki Shiraki et al.,  (2005)4 2   examined the impact of 
immunohistochemical expression of  markers on tumor 
progression in 140 oral  cancers and found that   p53,cyclin D1 
and EGFR (Epidermal Growth Factor Receptor)  were expressed 
in 64 cases (46%), 54 cases (39%) and 54 cases (39%)  
respectively and thus concluded that simultaneous coexpression 
of these markers in oral cancers might prove to be a useful 
indicator for identification of low- or high-risk patients.  Such 
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coexpression of multiple molecular markers is in close agreement 
with the fundamental concept of multistep cancer development 
and progression.  
 Punnya V. Angadi et al  . ,(2007)1 7   assessed the expression of 
cyclin D1 in 79 cases of  OSCC and VC  to compare its 
expression in both of these carcinomas, and found Cyclin D1 
overexpression  in 29 cases (70.7%) of OSCC and in 19 cases 
(63.3%) of VC. However no statistical signiﬁcance was observed 
in cyclin D1 expression between OSCC and VC but statistica l 
signiﬁcance was seen between VC and poorly differentiated 
squamous cell carcinoma. The study concluded that the increased 
expression of cyclin D1 signiﬁcantly correlated with lack of 
differentiation in  malignant epithelial neoplasms since the  
results suggested a possibility that cyclin D1 targets not only 
proliferation but also affec ts the differentiation of the cells in 
these oral  neoplasms
1 1
.   
 John P Alao (2007 )4 3   discussed the regulation of cyclin D1 
degradation and the therapeutic ablation of cyclin D1 which 
might  be useful for the prevention and treatment of cancer.  He 
had stated in his art icle that  in mammalian cells, DNA damage, 
environmental stress, genotoxic stress and viral infection have 
also been shown to induce the ubiquitin -dependent degradation 
of cyclin D1.  
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 Jong Kyong Kim and J. Alan Diehl (2009) 4 4  briefly provided 
overview of various mechanisms underlying aberrant cyclin D1 
regulation in human cancers and their impact on neoplastic 
transformation. Their observations suggested that  nuclear 
retention of active cyclin D1/CDK complex may be a critical  
determinant to el icit  the oncogenicity of cyclin D1 in addit ion to 
its prevalent overexpression in cancers and  its  CDK -
independent, nuclear receptor -agonistic activity  may also 
contribute to its  oncogenicity in certain types of cancers 
including breast cancer.  
 Satya N. Das et al.,  (2011)1 8  investigated the correlation 
between cyclin D1 overexpression,  clinicopathological  features 
and cell cycle parameters in patients with tobacco -related OSCC. 
Higher expression of cyclin D1 was observed only in 30 of 45 
cases that correlated with advanced age (P <0.02), higher tumour 
stage (P<0.01), histological  differentiation and lymph node 
metastasis (P <0.01). Analysis of nuclear DNA pattern revealed 
cyclin D1 immunoreactivity in tumours with aggressive DNA 
pattern such as aneuploidy (P<0.05) and higher S phase fraction 
(P<0.04). The study concluded that  higher expression of cyclin 
D1 in oral  cancer appeared to be closely linked to cell  
proliferation, differentiation and lymph node invasion. Therefore 
pre-operative evaluation of cyclin D1 in biopsy specimen may be 
useful in planning the most appropriate treatment strategies in 
patients with tobacco-related OSCC. 
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 Uma Swaminathan et al . ,  (2012)4 5  assessed p53 and cyclinD1 
expression using immunohistochemistry in 20 cases of OSCC  and 
10 normal mucosa and stated that p53 and cyclin D1 is amplified 
and overexpressed in oral  squamous cell carcinoma and a 
positive correlation is seen between increased mutant p53 
expression and cyclin D1 expression in OSCC.  
 Shiang-Fu Huang et al . , (2012)4 6   examined cyclin D1 protein 
expression using immunohistochemistry in 264 male s with OSCC 
and found  overexpression of cyclin D1  in 97 cases of  OSCCs  
which associated with lymph node metastasis, tumor cell  
differentiation  and tumor stage. The study  concluded that  cyclin 
D1 protein worked as an independent prognostic factor and can 
be as a biomarker for the aggressiveness of OSCC.  
 Swati Saawarn et al., (2012)47 immunohistochemically evaluated the 
expression of cyclin D1 in forty formalin -ﬁxed paraﬃn-
embedded tissue blocks of oral squamous cell  carcinoma and 
found highest expression in well -diﬀerentiated, followed by 
moderately differentiated, and poorly diﬀerentiated squamous 
cell carcinomas, with a statistically signiﬁcant correlation thus 
showing that Cyclin D1 expression signiﬁcantly increases with 
increase in diﬀerentiation.  
 Lai-ping Zhong et al . , (2013)4 8  performed immunohistochemical 
staining for cyclin D1 in pretreatment biopsy specimens of 232 
out of 256 clinical  stage III/ IVA OSCC patients randomized to 
the clinical trial . Cyclin D1 index was estimated as the 
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proportion of tumor cells with cyclin D1 nuc lear staining. A low 
cyclin D1 expression predicted significantly better overall  
survival, disease-free survival, locoregional recurrence -free 
survival and distant metastasis -free survival compared to high 
cyclin D1 expression. The results concluded that c yclin D1 
expression could be used as a biomarker in further validation 
studies to select patients who could benefit  from induction 
therapy.  
 Yanhui Zhao et al . ,  (2014)4 9   performed a comprehensive meta-
analysis for evaluation of cyclin D1 overexpression in oral  
squamous cell carcinoma to determine the strength of this 
association and  concluded that cyclin D1 expression correlated 
with detrimental clinicopathological outcome and poor prognosis 
in oral squamous cell carcinoma. So The prognostic value of  
cyclin D1, either alone or combined with alternative molecular 
markers, would be validated in clinical  practice.  
 Yuichi Ohnishi et al., (2014)50 conducted an immunohistochemical 
investigation of cyclin D1 and Ki -67 expression in OSCC to 
evaluate the correlations between cell differentiation, cell  
proliferation and metastasis, the effect of anticancer drug 
medication and cyclin D1 expression. Cyclin D1 and Ki -67 were 
detected clearly in the nuclei  of 35 SCC samples but no 
correlation was found between cyclin D1 p rotein expression and 
oral SCC differentiation. Their results indicated that the 
expression of cyclin D1 protein plays a role in cell 
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differentiation and cell proliferation in well -differentiated oral  
SCC and also the high expression of cyclin D1 may contr ibute to 
drug resistance in cancer cells,  not only by increasing cell 
proliferation, but also by suppressing cancer cell apoptosis.  
 Swati Saawarn et al.,  (2015)1 6  provided an insight into the 
physio-pathological role of cyclin D1 in Oral Squamous Cell  
Carcinoma and found  that there  is wide variation and diversity 
in the reports available in the l iterature regarding levels,  
diagnostic and prognostic significance of Cyclin D1 especially in 
oral Squamous cell carcinoma. The art icle also suggested that 
other than being used as a prognostic marker, cyclin D 1 is may 
also be used as a target molecule in cancer chemotherapy as 
tumors over-expressing cyclin D1 has been found to be more 
sensitive to chemotherapeutic agent Rapamycin.  
 Anand Choudhary et al.,(2016)24 performed an immunohisto 
chemical analysis in 50 cases of different grades of OSCC using 
anti‑cyclin D1 antibody and found  overexpression of cyclin D1 
in 68% cases with a significant correlation with younger age 
group and  also in the intergroup compar ison of the cyclin D1 
expression between well  differentiated OSCC and poorly 
differentiated OSCC.  
 Reena Rachel John et al .,  (2017)5 1  reviewed the multifaceted 
role played by cyclin D1 in various types of malignancies in 
different sites of the body and suggested that  cyclin D1 is a 
promising  tumor  marker  which can  aid in the diagnosing and 
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predicting the prognosis of OSCC. They stated that a range  of 
35%–64% of head and neck squamous carcinomas shows 
overexpression of cyclin D1 and  cyclin D1 ‑ negative tumors 
reacted, especially well to multimodality  treatment  
 Pablo Ramos-García et al .,  (2017)3 8   reported the  influence of 
CCND1/cyclin D1 on tumor size and clinical  stage and provided 
an update on the utilization of cyclin D1 as therapeutic target  
and on the combination of cyclin D1 inhibitors with cytotoxic 
agents. He emphasised that  cyclin D1 regulates cell migration 
and participates in metastatic development in OSCC and other 
tumours.  
 Sunit B. Patel et al . , (2017)5 2  compared cyclin D1 and p63 
expression in leukoplakia and OSCC to investigate the possible 
correlation of both markers with grade of dysplasia and 
histological grade of OSCC. Their study concluded that  the 
overall expression of cyclin D1 and p63 correlated  with tumor 
differentiation and  poor histological grades, from well -
differentiated to poorly-differentiated SCC. Increased cyclin D1 
and p63 expression was also associated with the severity of 
leukoplakia.  
 Pablo Ramos-García et al. ,  (2018)5 3  performed a systemic 
review and meta-analysis to evaluate the prognostic signiﬁcance 
of cyclin D1  overexpression in OSCC and showed that  cyclin D1 
overexpression had a strong statist ical association with worse 
overall survival, worse disease-free survival, higher T sta tus, N+ 
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status, advanced stage, and high histological grade. Their 
ﬁndings indicated that immunohistochemical assessment of 
cyclin D1 overexpression may be useful as a prognostic 
biomarker for OSCC and  patients with tongue SCC, the most 
frequent intraoral  site that  carries the worst  prognosis  can 
especially beneﬁt from the evaluation of cyclin D1 
overexpression in their prognostic assessment. According to their 
ﬁndings, cases should be considered posit ive when the 
percentage of tumor cells with nuclear cyclin D1 expression is  
10% or above.  
 
MCM2 EXPRESSION IN ORAL SQUAMOUS CELL CARCINOMA  
AND VERRUCOUS CARCINOMA 
 Isamu Kodani et al . ,(2001)5 4  examined cell cycle and cell death 
biomarker trends with the normal -dysplasia-carcinoma sequence 
of the oral epithelia analyzing the pathological significance of  
MCM2. The results showed significantly higher labeling indices  
of MCM2, Ki-67, and P53 in OSCCs than in the dysplasias and 
concluded that  MCM2  regulated via a P53 -independent pathway 
as a useful biomarker of proliferating cells.  
 IS Scott et al . ,  (2006)5 5   examined the potential utility of MCMs 
as candidate biomarkers for detecting oral  malignancy and 
dysplasia in 101 smears of oral lesions. Of 52 conventional 
smears of SCC tissue samples, 18 were inad equate and MCM-
positive cells were present in 33/34 adequate samples.  They 
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concluded that  MCMs are promising markers for early detection 
of oral SCC and dysplasia, particularly in a liquid -based 
cytology platform.  
 Jolanta Szelachowska et al . ,  (2006 )5 6   evaluated the expression 
intensities of the MCM-2 protein and Ki-67 antigen in 
squamocellular carcinomas of the oral cavity in forty -nine 
patients,  operated on and treated with radiotherapy and compared 
their prognostic value.  A significant positive correlat ion was 
noted between the expression of MCM -2 protein and that  of the 
Ki-67 antigen. The results suggested that  the expression of 
MCM-2 protein may be used as a prognostic factor in patients 
with squamocellular carcinoma of the oral cavity.  
 A Torres-Rendon et al . , (2009)2 8  identified the  the expression 
pattern of MCM2, Ki67 and geminin in normal oral mucosa ,oral  
epithelial  dysplasia, and   OSCC. MCM2 protein expression was 
found to be higher in the oral  epithelial  dysplasia with malignant 
progression and  there was a significant increase in the 
MCM2/Ki67 and geminin/Ki67 ratios  .  The study concluded that   
MCM2 and geminin proteins as  novel biomarkers of growth and 
hence  useful prognostic tools for oral epithelial  dysplasia.  
 Adriele Ferreira Gouveˆa et al . ,  (2010)5 7  evaluated the 
clinicopathological characteristics and the distribution of cell  
proliferation markers, p53, Ki-67, MCM-2 and MCM-5 aiming to 
elucidate the distinct biological behavior of the Proliferative 
verrucous leukoplakia ( PVL) in 12 patien ts for whom 47 
Review of Literature 
 
 Page 26 
 
biopsies were taken which showed  six cases of hyperkeratosis 
and acanthosis,  27 cases of mild dysplasia, three cases of  
moderate dysplasia,  four cases of severe dysplasia and seven of 
SCC. The immunohistochemical ﬁndings showed highe r 
positivity for p53, Ki-67, MCM-2 and MCM-5 in SCC and in 
some patients with mild or moderate dysplasia, specially the 
patients who developed SCC.  The results suggested that high 
immunoexpression of MCM-2 and MCM-5 in mild and moderate 
dysplasia could be helpfu l to predict the malignant 
transformation of proliferative verrucous leukoplakia.  
 Giaginis C et al . ,(2010)5 8   reviewed the the clinical  significance 
of MCM protein expression in human neoplasia in comparison to 
conventional proliferative markers and revealed that MCM 
expression is associated with important clinicopathological 
parameters for patient management and also exhibited significant  
diagnostic and prognostic value in several  malignancies.  MCMs 
was characterized by higher specificity and sensitivity than the 
conventional proliferative markers, such as Ki -67 and PCNA, 
and thus was considered as diagnostic and prognostic tools of 
greater clinical significance in several types of human 
malignancy.  
 L. A. Gueiros et al . ,  (2011)5 9   evaluated the clinicopathological 
features and immunohistochemical expression of proliferation 
markers Ki-67, MCM-2 and geminin in sixty-three patients 
without previous treatment or distant metastases of oral  tongue 
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squamous cell carcinomas (OTSCC ).  All markers showed a 
higher staining pattern on the periphery of the tumoural islands.  
MCM-2-positive cells were also present in the cen tral  portion of 
the tumours.  MCM-2 presented higher LI  fo llowed by Ki-67 and 
geminin. MCM-2 immunoexpression was related to nodal 
recurrence, geminin was statistically associated with perineural  
invasion,  Ki-67 presented a statistically signiﬁcant association  
with distant metastasis and MCM-2  was statistically related to 
nodal recurrence  and advanced disease stage. The results 
concluded that  Anneroth and Bryne score in association with 
biomarkers of proliferation can be useful for evaluating the 
biological  behaviour of OTSCC.  
 Heba N. Shalash et al . ,  (2012)3 4   conducted a study to examine 
the cellular distribution of MCM -2 in oral squamous cell  
carcinoma and their value to predict  lymph node metastasis.  
Significant difference in the expression of MCM -2 between the 
different grades of OSCC cases and a positive correlation  
between the percentage of cases with posit ive lymph node 
metastasis and the mean area percentage of MCM -2 expression 
was noted, hence concluding that oral  squamous cell  carcinomas 
express MCM-2 with variable levels and cellular localization, 
making i t  an important marker of biological behavior in OSCC.  
 Motahhary P et al .,  (2012)6 0   evaluated  the expression of 
MCM2 and D2-40 in tongue squamous cell carcinoma (TSCC) 
and investigated their relation with lymph node metastasis and 
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patient survival. Lymphatic vessel  density (LVD) was 
determined by D2-40 evaluation and MCM2 labell ing index (LI)  
was also determined by counting of the positive cells.  The result 
showed that the LVD of the group with lymph node metastasis 
was signiﬁcantly higher than lymph node negative group and also 
showed a signiﬁcant relation with patients survival but th ere was 
no signiﬁcant relation between MCM2 LI and lymp node 
metastasis. Hence, the study concluded  that D2 -40 could be used 
as a marker in predicting nodal metastasis in TSCC.  
 Ramón Gil Carreón-Burciaga et al. ,(2015)6 1  analyzed the 
presence of Ki-67 protein,  MCM2 and MCM3 proteins in 
ameloblastoma and found that  MCM2 and MCM3 showed higher 
proliferation indexes in ameloblastoma compared to Ki -67. Their 
results suggested MCM2 and MCM3 are more sensitive markers 
of cell proliferation.  
 Seyed Mohammad Razavi et al. ,(2015)3 6  investigated the 
diagnostic value of MCM-2 expression in distinguishing 
histologically-proven normal oral mucosa, oral benign keratosis ,  
oral epithelial dysplasia ,  and OSCC. Overexpression of MCM2 
was noted with higher positivity in OSCCs and their findings 
indicated that MCM-2 could be a useful marker for early 
detection of OSCC and dysplasia.  
 Samar H. Zakaria et al . , (2016)6 2  assessed the cell proliferative 
activity of MCM-2 in oral epithelial  dysplast ic lesions and  
correlated the results with diﬀerent grades of epithelial dysplasia 
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and found that   MCM-2 immunostaining was found to increase 
gradually from mild to moderate to severe dysplasia and reached 
its maximum value in early invasive squamous cell  carcinoma. 
The study concluded that MCM-2 has prognostic value in cases 
of oral dysplasia that have a tendency to undergo malignant 
transformation.  
 Kochli  Channappa Niranjan et al . , (2018)6 3  assessed the 
expression of MCM-2 in Normal Oral Mucosa, Verrucous  
Hyperplasia , Verrucous Carcinoma and OSCC and compared it  
with the clinicopathological  characteristics. There was a 
signiﬁcant diﬀerence in MCM-2 expression with quantitative 
analysis among all  the groups  And there was a signiﬁcant  
progressive increase in nuclear Labelling Indices  from normal 
mocosa (49.08%), Verrucous Carcinoma (60.45%), Verrucous 
Hyperplasia with Dysplasia (64.10%)  and OSCC (89.22%). Their 
ﬁndings suggested that  MCM -2 may be useful for diﬀerentiating 
between Verrucous Hyperplasia with / without dysplasia,  
Verrucous Carcinoma and OSCC.  
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CYCLIN D1 IN OTHER TUMOURS 
 Aleena Gladkikh et al. ,  (2010)6 4  determined the level of cyclin 
D1 expression in various B-cell lymphomas and observed that  
mantle cell  lymphoma had the level of Cyclin D1  signiﬁcantly 
elevated above that  of normal lymphocytes.  
 Fereshteh Mohammadizadeh et al . , (2013)6 5  did a cross-
sectional investigation in 89 patients with breast  invasive ductal 
carcinoma and found reverse relationship between cyclin D1 
overexpression and tumor grade  
 Yang Li et al . , (2014)6 6  observed that cyclin D1 overexpression 
was significantly associated with both poor overall  survival  and 
disease free survival in colorectal carcinoma.  
 Cheng-Han Lee et al. ,  (2012)6 7  identified diagnostic 
immunomarkers for biologically-defined Endometrial Stromal 
Sarcoma and observed  upregulation of cyclin D1.  
 Somanath Padhi et al . ,  (2013)6 8  studied the pattern of cyclin D1 
expression in 14 symptomatic patients of Multiple Myeloma  and 
observed Cyclin D1 expression was observed in 8 of 14 cases.  
 R.A. Pereira et al. ,  (2014)6 9  assessed cyclin D1 expression in 85 
patients who underwent radical p rostatectomy for prostate 
carcinoma and observed high expression of cyclin D1  associated 
with a high-grade Gleason score (≤7) and the presence of 
perineural invasion.  
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MCM2 EXPRESSION IN OTHER TUMOURS 
 EJ Davidson et al . ,(  2003)7 0  investigated the expression of 
proliferation markers in Vulval intraepithelial neoplasia and 
detected Cyclins B1 and  Cyclin D1 through the full  thickness of 
the  lesions.  
 Muhammad Zain Mehdi et  al. ,  (2016)7 1  assessed the prognostic 
significance of MCM-2 and Ki-67 in renal cell  carcinoma and 
found that Labeling index (LI)  of MCM -2  was found to be much 
higher than Ki -67.   
 Katarzyna Nowinska et al . ,(2016)7 2   studied the correlat ion 
between levels of expression of  MCM proteins,  Ki -67 proliferat ion 
antigen and metallothionein I/II (MT-I/II) in  83 laryngeal  
squamous cell  cancer (LSCC)  cases.  Strong positive correlat ion 
was noted between expression of MCM2, MCM3, MCM7 and Ki -67 
antigen in LSCC.  
 Bozena Werynska et al . ,(2011)7 3   observed a positive correlation 
between expression of metallothionein I/II  and expressions of Ki -
67  and MCM-2 in non-small cell  lung cancer.  
 H Gakiopoulou et al . ,  (2007)7 4  observed that the median MCM-2 
and MCM-5 labelling indices (LIs)  were significantly higher in 
adenocarcinomas and the levels of MCM-2 and MCM-5 increased 
significantly with advancing tumour stage.  
 Einas M Yousef et al. ,  (2017)7 5   studied  the expression of MCM2 
and Ki-67 in different histological  grades and molecular subtypes 
of breast cancer and found that MCM2 and Ki -67 were highly 
expressed in breast tumors of high histological grades.  
Materials and Methods 
 
 Page 32 
 
MATERIALS AND METHODS  
 
MATERIALS  
PARAFFIN BLOCKS:  
 Paraffin embedded tissues of histologically confirmed cases of 
Oral Squamous Cell Carcinoma, verrucous carcinoma and normal 
mucosa were used in the study.  
 
EQUIPMENTS:  
 Soft tissue microtome (Thermo scientific,  MICROM HM340E)  
 Paint brush  
  Disposable microtome blades  
  Hot plate  
  Hot water bath  
 Pathn Situ positively charged slides  
 Pressure cooker (5 Liters)  
 Measuring Jars  
 Coplin Jars  
  Electronic Timer  
 Absorbent wipes  
  Coverslip for slides  
  Binocular Light Microscope (Olympus CX21i)  
  Micropipette  
 Micropipette tips  
  Rectangular steel  trough  
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 Tweezer 
 Induction stove  
 Incubator (Hitech Equipments)  
 Liquid repellent slide marking pen  
 Deparaffinization stainless steel staining trough and rack  
 pH meter (E1 digital  pH meter)  
 A DELTA PLAN2 AP40 Trinocular Light Microscope with 
camera Head  
 
ANTIBODIES:  
1. Primary antibody  
(a)  Anti cyclin D1 [Rabbit monoclonal antibody] –  EP12 (PathnSitu 
Biotechnologies Private Limited)  
(b)  Anti MCM 2 [Rabbit monoclonal antibody] –  EP40 (PathnSitu 
Biotechnologies Private Limited)  
 
2. Secondary kit (PolyExcel HRP/DAB Detection System) –  Pathn Situ 
Biotechnologies Private Limited  
a.  PolyExcel H2 O2  
b.  PolyExcel Target Binder  
c.  PolyExcel Poly HRP  
d.  PolyExcel stunn DAB –  Chromogen 
e.  PolyExcel stunn DAB –  Buffer  
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REAGENTS:  
  Tris-EDTA Buffer –  50X concentration (PathnSitu 
Biotechnologies Private Limited)  
  Immuno wash Buffer –  25X concentration (PathnSitu 
Biotechnologies Private Limited)  
   Distilled water  
   Xylene 
  Absolute alcohol (Isopropyl Alcohol)  
  Alcohol 90% (Isopropyl Alcohol)  
   Alcohol 70% (Isopropyl Alcohol)  
   Harris Hematoxylin  
   Mountant (Dibutyl  Phthalate Xylene)  
 
STUDY DESIGN AND PATIENT SELECTION:  
 This immunohistochemical  study was conducted on the archival 
retrieved from the formalin fixed, paraffin embedded tissues retrieved 
from the archives of the Department of Oral and Maxillofacial 
Pathology, Adhiparasakthi Dental  College and Hospital, 
Melmaruvathur. The study group included 20 cases of 
histopathologically diagnosed Oral Squamous Cell Carcinoma (10 cases 
of well differentiated squamous cell  carcinoma, 10 cases of Moderately 
differentiated Squamous Cell Carcinoma) and 10 cases of 
histopathologically diagnosed verrucous  carcinoma. Control group 
included 10 biopsies from the normal buccal mucosa adjacent to the 
site of surgery during the surgical  removal of third molars in  patients.   
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For posit ive control ,  archival retrieved formalin fixed, paraffin 
embedded tonsil  tissue  was obtained from the Department of General 
Pathology, Melmaruvathur Adhiparasakthi Insti tute of Medical Science 
and Research, Melmaruvathur.  
 
IHC METHODOLOGY: 
 Formalin fixed paraffin embedded tissues were sectioned at  3µm 
and mounted on positively charged slides. The sl ides were  kept  
for  incubation at 37
o
C overnight.  
 The slides were deparaffinized by 2 changes of xylene for a  
duration of 10 minutes each. 
 The slides were hydrated through descending grades of alcohols 
as follows:  
  Absolute alcohol –  1 change, 5 minutes  
  90% alcohol –  5 minutes  
  70% alcohol –  5 minutes  
 The slides were washed in distilled water ( 2 changes, 5 minutes  
each).  
 Antigen retrieval was done using Tris EDTA (Ethylene Diamine 
Tetra Acetic acid )  buffer  by  pressure cooker method (15- 20 
minutes,  upto 2 whistles) and cooled for about 30 minutes .  
 The slides were washed in distil led water ( 2 changes, 3 minutes 
each).  
 Using liquid repellent pen, c ircles were marked enclosing the 
section. 
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 PolyExcel H2O2  (Hydrogen Peroxide) was added on the section, 
kept for 10 minutes  and endogenous peroxidase blocking was 
done.   
 The slides were washed in wash buffer(  5 minutes, 2 changes) 
 Primary antibody was added and kept for 45 minutes for cyclin 
D1  and  MCM2 in a moist chamber  
 The slides were washed in wash buffer(  5 minutes, 2 changes)  
 PolyExcel Target Binder reagent was added and kept for 
incubation for 12 minutes  
 The slides were washed in wash buffer(  5 minutes, 2 changes)  
 Polyexcel HRP(Horse Radish Peroxidase)  was added and 
incubated for 12 minutes  
  DAB(Diamino benzidine)  solution was prepared (1 ml of DAB 
buffer + 1 drop DAB chromogen and  mixed well)  
 The slides were washed in wash buffer( 5 minutes, 3 changes)  
  Working DAB chromogen was added, kept for 5 min utes and  
then washed in distil led water.  
 The slides were counterstained with Harris hematoxylin for 30 
seconds and washed in running tap water for 5 minutes  
 The slides were dehydrated through successive changes of 
alcohol,  cleared with xylene, dried and mounted with DPX 
(Distyrene Plasticizer Xylene).  
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POSITIVE CONTROLS 
Positive control  section included tonsil   for Cyclin D1 (Figure 8)  
and MCM 2 (Figure 22)and was treated in the same manner as the test  
groups.  
 
NEGATIVE CONTROLS 
One section of test sample was selected and treated in the same 
manner as the test  groups except that, the primary antibody was 
omitted for both Cyclin D1 and MCM 2.  
 
ANALYSIS OF AREA OF STAINING  OF CYCLIN D1 AND MCM 2  
To know the expression pattern and a lso to determine the levels 
of protein expression in the epithelial  layers,  area of staining was 
analysed. It  was determined by scanning the entire section of the 
epithelium at 4 X magnification and area of stained epithelial cells is  
recorded as:
 
SCORE INFERENCES 
0 0% 
1 <25% 
2 25 - 49% 
3 50 - 74%  
4 75 - 100% 
 
The staining intensity was calculated for Cyclin D1 and MCM2  
in WDSCC, MDSCC, VC and NM.  
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ANALYSIS OF STAINING INTENSITY OF CYCLIN D1 AND 
MCM2 : 
To know the extent of stain uptake, intensity of staining was 
analysed. Ten random fields were selected at  40 X magnifications in 
each slide. Sections were scored for staining intensity and scaled as 
follows
1 7 ,2 3 ,2 4
:  
SCORE INFERENCES 
0 No stain 
1 Mild staining 
2 Moderate staining  
3 Intense staining 
 
The staining intensity was calculated for Cyclin D1 and MCM2  
in WDSCC, MDSCC, VC and NM.  
 
ANALYSIS OF LABELLING INDEX (LI)   OF CYCLIN D1 AND 
MCM 2 :  
The slides were examined under a light microscope (Olympus 
CX21 i) at 40 X  magnification and  representative photomicrographs 
were taken in five hotspot areas for each slide. The photomicrographs 
were then analysed using image processing program (ImageJ,  
http://imagej.nih.gov/ij/).  Percentage of IHC positive tumour cells per 
hot spot (A) was calculated and total number of tumour cells in each 
slide was calculated till  a minimum of 400 cells
 
were reached i .e the 
sum of the denominators (x)
2 4
.   
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Percentage of positive nuclei (Labeling index -LI) in each case 
was calculated using the formula
3 4
 
LI %    =    A                     X 100  
  Total no. of tumor cells(x)  
 
The Labelling Index (LI) was calculated for Cyclin D1 and 
MCM2  in WDSCC, MDSCC, VC and NM.  
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Figure 4: Primary and Secondary Antibody kit  
 
                        
 
  
 
                                     
 
 
 
 
 
 
Figure 4a :  Primary antibody Anti – 
Cyclin D1 [Rabbit Monoclonal] 
Figure 4b :  Primary antibody Anti – 
MCM 2  [Rabbit Monoclonal] 
Figure 4c : Secondary Antibody kit 
[H2O2, Target Binder, Poly HRP] 
Figure 4d : DAB Chromogen and 
DAB buffer 
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Figure 5: Reagents  
 
    
 
 
 
 
 
 
 
Figure 5a : Tris- EDTA Buffer 
 
Figure 5b : Hematoxylin 
 
Figure 5c : Wash Buffer 
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Figure 6:  Equipments  
 
 
                 
                   
                                                                                      
 
 
 
Figure 6a : Deparaffinization stainless steel staining trough and rack 
 
Figure 6b : Micropipette 
 
Figure 6c : Incubator 
Figure 6d : Reagent Blocker Pen 
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Figure 6e : Microtome 
 
Figure 6f : Microscope 
 
Figure 6g  : pH Meter 
 
Materials and Methods 
 
 Page 44 
 
 
                               7.  Determination of Labelling Index 
 
 
 
 
 
Figure 7a: Photomicrograph showing counting of IHC positive tumour cells using ImageJ software 
Figure 7b: Photomicrograph showing counting of total number of  tumour cells in the field 
using ImageJ software 
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RESULTS 
  
 A retrospective cross sectional immunohistochemistry study was 
carried out on 40 archival retrieved formalin fixed paraffin embedded 
tissue blocks divided into 4 groups comprising of  20 
histopathologically diagnosed cases of OSCC, 10 cases of Verrucous 
Carcinoma and 10 cases of normal  mucosa (NM) to study the 
expression of CyclinD1 and MCM2, cell proliferation biomarkers. 20 
OSCC cases were further divided into 2 subgroups; Well  differentiated 
SCC (n=10) and Moderately differentiated SCC (n=10 ).  
 
 The presence of brown coloured end product at the site of target 
antigen indicated positive staining. All the cases showed variable 
intensities of nuclear staining. The present study involved both 
qualitative and quantitative analysis.  Qualitative ana lysis was done by 
evaluation of intensity of staining and area of staining.  
 
 For assessing the intensity of staining 10 random fields were 
selected under 40x magnification and scored as 0- no stain, 1- mild 
stain, 2-moderate stain and  3-intense stain. For assessing the area of 
staining the entire section of the epithelium was scanned and area of 
stained epithelial  cells were recorded as 0- 0%, 1- <25%, 2- 25 to 49%, 
3- 50 to 74%, 4- 75 to 100%.  
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 Quantitative analysis was done by calculating the percenta ge of 
positively stained cells. Representative fields were selected in each 
case and up a minimum of 400 tumor cells were counted and the 
percentage (%) of their positivity was determined.  The % of positivity 
was denoted as labelling index (LI).  
   
1.Determination and comparison of the intensity of expression and area  
of staining  of Cyclin D1 in NM, WDSCC, MDSCC and  VC  
 Cyclin D1 positivity was seen in all cases except one case of 
MDSCC. The observations of staining intensity and area of staining of  
Cyclin D1 in the present study are tabulated in Table 1 and Table 2 
respectively.  
 
Table 1: Staining  intensity of  Cyclin D1 among the study groups  
SAMPLE n 
CYCLIN D1 -INTENSITY OF STAINING 
NO  STAIN MILD MODERATE INTENSE 
NM 10 0 6 3 1 
WDSCC 10 0 0 2 8 
MDSCC 10 1 2 2 5 
VC 10 0 3 3 4 
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Table 2:  Area of Staining of  Cyclin D1 among the study groups  
SAMPLE n 
CYCLIN D1 -AREA OF STAINING 
SCORE 
0 
SCORE 
1 
SCORE 
2 
SCORE 
3 
SCORE 
4 
NM 10 0 6 3 1 0 
WDSCC 10 0 0 2 4 4 
MDSCC 10 1 6 1 1 1 
VC 10 0 6 2 2 0 
 
 The mean score for intensity of staining for NM, WDSCC, 
MDSCC and VC were found to be 1.5 (SD 0.7), 2.8 (SD 0.4), 2.1 (SD 
1.1) and 2.1 (SD 0.8) respectively.  The difference between the mean 
scores was found to be statistically significant (p< 0.05) using Kruskall  
Wallis’ ANOVA  (Table 3) (Graph 1) .  
 
 The mean score for area of staining for NM, WDSCC, MDSCC 
and VC were found to be 1.5 (SD 0.7), 3.2 (SD 0.7),  1.5 (SD 1.1) and 
1.6 (SD 0.8) respectively.  The difference between the mean scores was 
found to be statistically significant  (p<0.05)  using Kruskall Wallis’ 
ANOVA (Table 3) (Graph 1) .  
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TABLE 3: Comparison of Cyclin D1 intensity and area  of  staining 
between the study groups 
 
n Mean 
Std. 
Deviation 
Mean 
Rank 
Chi-
Square 
P-
value 
CyclinD1-
Intensity of 
staining 
 
NM 10 1.500 0.707 12.60 
10.897 0.012* 
WDSCC 10 2.800 0.422 28.70 
MDSCC 10 2.100 1.101 20.75 
VC 10 2.100 0.876 19.95 
Cyclin D1-
Area of 
Staining 
NM 10 1.500 0.707 16.50 
15.864 0.001* 
WDSCC 10 3.200 0.789 32.50 
MDSCC 10 1.500 1.179 15.70 
VC 10 1.600 0.843 17.30 
 
* denotes statistically significant using Kruskall Wallis’ ANOVA  
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Graph 1: Comparison of Cyclin D1 intensity and area  of staining 
between the study groups 
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2.Determination and comparison of the intensity of expression and area  
of staining  of MCM 2  in  NM,WDSCC,  MDSCC and VC.  
 MCM2 positivity was seen in all cases. The observations of 
staining intensity and area of staining of MCM 2  in the present study 
are tabulated in Table 4 and Table 5 respectively.  
 
Table 4:  Staining  intensity of  MCM2 among the study groups  
SAMPLE n 
MCM2 -INTENSITY OF STAINING 
NO STAIN MILD MODERATE INTENSE 
NM 10 0 2 5 3 
WDSCC 10 0 0 0 10 
MDSCC 10 0 2 0 8 
VC 10 0 1 2 7 
 
 
Table 5: Area of Staining of  MCM2 among the study groups  
SAMPLE n 
MCM2 -AREA OF STAINING 
SCORE 
0 
SCORE 
1 
SCORE 
2 
SCORE 
3 
SCORE 
4 
NM 10 0 4 5 1 0 
WDSCC 10 0 0 1 2 7 
MDSCC 10 0 2 2 1 5 
VC 10 0 3 2 3 2 
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The mean score for intensity of staining for NM, WDSCC, 
MDSCC and VC were found to be 2.1 (SD 0.7), 3.0 (SD 0.0), 2.6 (SD 
0.8) and 2.6 (SD 0.6) respectively.  The difference between the mean 
scores was found to be statistically significant (p<0.05) using Kr uskall  
Wallis’ ANOVA  (Table 6) (Graph 2) .  
 
 The mean score for area of staining for NM, WDSCC, MDSCC 
and VC were found to be 1.7 (SD 0.6), 3.6 (SD 0.6),  2.9 (SD 1.2) and 
2.4 (SD 1.1) respectively.  The difference between the mean scores was 
found to be stat istically significant  (p<0.05) using Kruskall Wallis’ 
ANOVA (Table 6) (Graph 2) .  
 
TABLE 6:  Comparison of  MCM 2 intensity and area of staining 
between the study groups 
 
n Mean 
Std. 
deviation 
Mean 
Rank 
Chi-
Square 
P-
value 
MCM2-
Intensity 
of 
Staining 
NM 10 2.100 0.738 13.05 
10.492 0.015* 
WDSCC 10 3.000 0.000 26.50 
MDSCC 10 2.600 0.843 21.80 
VC 10 2.600 0.699 20.65 
MCM2-
Area of 
Staining 
NM 10 1.700 0.675 11.55 
13.708 0.003* 
WDSCC 10 3.600 0.699 29.50 
MDSCC 10 2.900 1.287 22.95 
VC 10 2.400 1.174 18.00 
* denotes statistically significant using Kruskall Wallis’ ANOVA  
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Graph 2:  Comparison of MCM 2 intensity and area of staining 
between the study groups 
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3. Comparison of staining intensities and area of staining between 
Cyclin D1 and MCM2 in WDSCC, MDSCC and  VC  
 On comparing the intensities of expression of  staining between 
Cyclin D1 and MCM2 in well differentiated squamous cell  carcinoma, 
statistically insignificant value (p> 0.05 ) was obtained by using Mann 
Whitney U test.  This could be because both markers predominantly 
showed intense staining (score 3) in WDSCC (Table 7) (Graph 3) .  
  
 Similarly on comparing the area of  staining between Cyclin D1 
and MCM2 in well differentiated squamous cell carcinoma, statistically 
insignificant value (p> 0.05 ) was obtained by using Mann Whitney U 
test . This could be because both markers predominantly showed 74-100 
%  posit ive cells (score 4) in WDSCC (Table 7)  (Graph 3).  
  
 On comparing the intensities of expression of staining between 
Cyclin D1 and MCM2 in MDSCC, statistically insignificant value (p> 
0.05 ) was obtained by using Mann Whitney U test.  (Table 7) (Graph 
3). This could be because both markers predominant ly showed intense 
staining (score 3) in MDSCC. 
  
 Similarly on comparing the area of  staining between Cyclin D1 
and MCM2 in MDSCC, statist ically significant value (p< 0.05 ) was 
obtained by using Mann Whitney U test  (Table 7) (Graph 3) .  
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 Though Cyclin D1 predominantly showed moderate to intense 
staining (score 2 and 3) and MCM 2 predominantly showed intense 
staining (score 3),  on comparing the intensities of expression of  
staining between Cyclin D1 and MCM2 in VC, statist ically 
insignificant value (p> 0.05 ) was obtained by using Mann Whitney U 
test  (Table 7) (Graph 3) .  
 
 Similarly on comparing the area of  staining between Cyclin D1 
and MCM2 in VC, statistically insignificant value (p>  0.05 ) was 
obtained by using Mann Whitney U test. This can be because in VC, 
Cyclin D1 showed mostly < 24% positive cells (score 1) whereas 
MCM2 showed both < 24% and 74 -100 % positive cells (score 1 and 4) 
(Table 7) (Graph 3).  
 
TABLE 7: Comparison between Cyclin D1 and MCM2 staining 
intensity and area of staining  in WDSCC, MDSCC and VC  
Comparison 
 
WDSCC MDSCC VC 
n Mean STD 
P-
Value 
Mean STD 
P-
Value 
Me
an 
STD 
P-
value 
Cyclin D1- I 10 2.8.  0.422 
0.157 
2.1 1.101 
0.059 
2.1 0.876 
0.248 
MCM 2 - I 10 3 0 2.6 0.843 2.6 0.699 
Cyclin D1- 
A 
10 3.2 0.789 
0.102 
1.5 1.179 
0.011* 
1.6 0.843 
0.066 
MCM2 -A 10 3.6 0.699 2.9 1.287 2.4 1.174 
* denotes statistically significant using Mann Whitney U test  
I –  Staining Intensity                 A –  Area of Staining 
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Graph 3: Comparison between Cyclin D1 and MCM2 staining  
intensity and area of staining  in WDSCC, MDSCC and VC 
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4. Comparison of Labelling Index (LI) of  Cyclin D1  among  the study 
groups 
The LI of cyclin D1 in Normal buccal  mucosa ranged from 
2.48%-17.03% with the mean score of  8.42  (SD -5.10).  The LI of 
cyclin D1 in OSCC ranged from 11.78% - 30% with the mean value of  
20.086 (SD-6.840). The LI of cyclin D1 in VC ranged from 9.34% - 
44.48% with the mean score  of 21.68  (SD-10.90).  
 
On comparison of Labelling Index (LI)  of cyclin D1  between the 
groups, statistically significant value (p<0.05) was obtained (Table 8)  
using Kruskall Wallis’ ANOVA .  
 
TABLE 8 : Comparison of Labelling Index (LI)  of  Cyclin D1  
between the study groups  
 n Mean 
Std. 
Deviation 
Mean 
ranks 
Chi-
square 
P-value 
Cyclin 
D1 LI 
NM 10 8.410 5.098 8.3 
14.545 0.001* OSCC 20 20.086 6.840 24.8 
VC 10 21.681 10.901 24.1 
* denotes statistically significant using Kruskall Wallis’ ANOVA  
 
 
 
 
 
Results 
 
 Page 57 
 
5. Comparison of  Labelling Index (LI)  of  MCM 2  among the study 
groups 
 The LI of MCM 2 in Normal buccal mucosa ranged from 12.58% 
- 22.56%. The mean score was 18.33 (SD-3.99). The LI of MCM 2 in 
OSCC ranged from 15.39% - 69.66% with the mean value of 43.599 
(SD-15.330). The LI  of  MCM 2  in VC ranged from 10.08% - 64.43% 
with the mean value of 40.67  (SD-19.84). 
 
On comparison of Labelling Index (LI)  of  MCM 2  between the 
study groups, stat istically significant value (p<0.05) was obtained 
(Table 9)  using Kruskall Wallis’ ANOVA.  
 
TABLE 9 : Comparison of Labelling Index (LI) of  MCM 2  among 
the study groups  
 n Mean 
Std. 
Deviation 
Mean 
ranks 
Chi-
square 
P-
value 
MCM2 
LI 
NM 10 18.331 3.993 8.4 
14.451 0.001* OSCC 20 43.599 15.330 25.15 
VC 10 40.667 19.836 23.3 
* denotes statistically significant using Kruskall Wallis’ ANOVA  
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6. Comparison of  Labell ing Index (LI)  between Cyclin D1  and 
MCM2  in NM,  OSCC and VC  
 On  comparing the   Labelling Index (LI)  between Cyclin D1  
and MCM2  in normal mucosa, statistically significant valve was 
obtained (p< 0.05) using Mann Whitney U test  ( Table 10) (Graph 4) .  
 
On   comparing the   Labelling Index (LI)  between Cyclin D1  
and MCM2  in OSCC, statistically significant valve was obtained (p< 
0.05) using Mann Whitney U test  (  Table 10) (Graph 4) .  
 
On comparing the  Labelling Index (LI)  between Cyclin D1  and 
MCM2  in Verrucous Carcinoma, statistically significant valve was 
obtained (p< 0.05) using Mann Whitney U test  ( Table 10) (Graph 4) .  
 
TABLE 10 : Comparison of  Labelling Index (LI)  between Cyclin 
D1  and MCM2  in NM, OSCC and VC 
Comparison 
NM 
(n=10) 
OSCC 
(n=20) 
VC 
(n=10) 
Mean STD 
P-
value 
Mean   STD 
P-
value 
Mean STD 
P-
Value 
Cyclin D1 
LI 8.41 5.098 
0.007* 
20.086 
  
6.840 
0.001* 
21.681 10.902 
0.017* 
 
MCM2 LI 18.331 3.993 43.599 
  
15.330 40.667 19.836 
* denotes statistically significant using Mann Whitney U test  
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Graph 4: Comparison of  Labelling Index (LI)  between Cyclin  D1  
and MCM2  in NM, OSCC and VC 
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IMAGES –CYCLIN D1 
 
  
 
 
 
  
 
 
 
 
 
FIGURE 8:  cyclin D1 expression in positive 
control Tonsil  at 10 X magnification 
FIGURE 9:  Photomicrograph showing H & E 
stained section of WDSCC at 10 X magnification 
 
FIGURE 10:  Cyclin D1 expression in WDSCC 
with  more than 75 % of area of staining                 
(score 4) at 4 X magnification 
 
FIGURE 11:  Cyclin D1 expression in WDSCC 
with  50- 74 % of area of staining (score 3) at 
10 X magnification 
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FIGURE 12:  Cyclin D1 expression in WDSCC 
with  intense  staining (score 3) at 10 X 
magnification 
 
FIGURE 13:  Cyclin D1 expression in WDSCC 
with  intense  staining (score 3) at 40 X 
magnification 
 
FIGURE 14:  Photomicrograph showing 
H & E stained section of MDSCC at 10 X 
magnification 
 
FIGURE 15:  Cyclin D1 expression in MDSCC 
with  less than 25% of area of  staining (score 1) 
at 4 X magnification 
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FIGURE 16:  Cyclin D1 expression in MDSCC 
with  moderate  staining (score 2) at 10 X 
magnification 
 
FIGURE 17:  Photomicrograph showing H & 
E stained section of  VC at 10 X magnification 
 
FIGURE 18:  Cyclin D1 expression in VC  
with  50- 74% of area of staining (score 3) at 4 
X magnification 
 
FIGURE 19:  Cyclin D1 expression in VC  with  
mild staining (score 1) at 10 X magnification 
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FIGURE 20:  Photomicrograph showing H 
& E stained section of  NM at 10 X 
magnification 
 
FIGURE 21:  Cyclin D1 expression in NM  
with  mild staining (score 1) at 10 X 
magnification 
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IMAGES  - MCM 2 
 
  
 
 
 
 
 
  
 
 
 
 
 
 
FIGURE 22:  MCM 2 expression in positive 
control tonsil   at  10 X magnification 
FIGURE 23:  Photomicrograph showing H 
& E stained section of WDSCC at 10 X 
magnification 
 
FIGURE 24: MCM2  expression in WDSCC 
with  more than 75 % of area of staining 
(score 4) at 10 X magnification 
 
FIGURE 25: MCM2  expression in WDSCC 
intense staining (score 3) at 40 X 
magnification 
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FIGURE 26:  Photomicrograph showing H 
& E stained section of MDSCC at 10 X 
magnification 
 
FIGURE 27: MCM2  expression in MDSCC 
with  50- 74 % of area of staining (score 3) 
at 10 X magnification 
 
FIGURE 28: MCM2  expression in MDSCC with  
moderate staining (score 2) at 40 X magnification 
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FIGURE 31: MCM2  expression in VC with  
intense  staining (score 3) at 10 X 
magnification 
 
FIGURE 32: MCM2  expression in VC 
with  intense  staining (score 3) at 40 X 
magnification 
 
FIGURE 29: Photomicrograph showing H & E 
stained section of VC at 10 X magnification 
FIGURE 30: MCM2  expression in VC with  
50-74% of area of staining (score 3) at 4 X 
magnification 
 
Results 
 
 Page 67 
 
 
 
  
 
 
 
 
 
 
 
 
 
Figure 33:  Photomicrograph showing  
H & E stained section of NM at 10 X  
magnification 
 
Figure 34: MCM 2 expression in NM with less 
than 25 % of area of  staining (score 1) at 10 X  
magnification 
 
Figure 35: MCM 2 expression in NM with 
moderate  staining (score 2) at 10 X  magnification 
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DISCUSSION  
   
 Oral squamous cell  carcinoma (OSCC), represents over 90% of 
malignancies of the oral cavity
1
.  Despite the advances in diagnosis and 
therapy, OSCC continues to have a shorter survival rate.   Verrucous 
carcinoma of the oral  cavity,  a low grade variant of  OSCC  is 
considered  a  separate clinicopathologic entity due to i ts unique 
biologic behavior  and  limited propensity to metastasize
4
.  Tobacco is a 
major causative factor for  OSCC and VC,   and for a better 
understanding, it  is of  utmost importance to have an in -depth 
knowledge of the process of carcinogenesis in both these lesions.   
Carcinogenesis occurs due to genetic alterations,  paramount among 
them are those   genes  involved in   cell proliferati on. The study of 
cell proliferation is important for assessing the tumor behaviour,  
prognosis and patient survival
1 1
.  
 
Numerous proliferation markers have been developed to detect  
and quantify proliferation of cells in OSCC
1 1
.   Since cyclin D1 and 
MCM2  proteins act   by stimulating the cell cycle, few  studies have 
been carried out in order to determine whether alterations in expression 
of these biomarkers are related to carcinogenesis.  As literature search 
did not reveal sufficient  studies  of immunohistochemical expression of 
Cyclin D1 and MCM2 in OSCC and VC, the present study has been 
done to evaluate the  expression of these two cell proliferation 
biomarkers (Cyclin D1 and MCM2)  in  Oral Squamous cell  carcinoma, 
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and  Verrucous carcinoma using commercially available antibodies and  
paraffin-embedded tissue sections.  
  
 In the present study, a total of 80 samples out of which 40 
samples of OSCC, 20 samples of VC and 20 samples of normal NM 
were evaluated for the expression of Cyclin D1 a nd MCM 2 using 
standard IHC procedure with anti  Cyclin D1 [Rabbit  monoclonal  
antibody –  EP12 (PathnSitu Biotechnologies Private Limited)] and anti 
MCM 2 [Rabbit  monoclonal antibody –  EP40 (PathnSitu 
Biotechnologies Private Limited)]  
  
 The IHC reactivity was evaluated on the presence or absence of 
brown coloured end product stain at the site of target  antigen. All  the 
cases showed variable intensities of nuclear staining. In the present 
study,  in normal  mucosa 60% of the cases showed mild staining  
intensity of Cyclin D1 in the nucleus of  basal cells and few cells in 
the parabasal  layer (Figure 21) which   is  similar to the study results of 
Uma  Swaminathan et al
4 5
 and Angadi and Krishnapillai
1 7
.   
  
 However   in the present study 80% of cases showed  intense 
staining for cyclin D1 in WDSCC (Figure 12 and 13)  which is similar  
to the results of Yuchi Ohnishi et al
5 0
 in which 90% of metastatic foci  
in WDSCC showed strong staining of cyclin D1. This is  in contrast to  
the study of Sunit B. Patel  et al ,
5 2
  Angadi  and Krishnapillai
1 7
 and  
Goto et al
7 6  
where mild to moderate intensity of staining was observed 
in WDSCC.  
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Similarly,  50% of cases showed intense staining for cyclin D1 in 
MDSCC (Figure 16) and 50% of cases showed moderate stain ing for 
cyclin D1 in MDSCC which is nearly similar to the observations of   
Uma  Swaminathan et al
4 5
.  This is  in contrast  to the study of   Angadi 
and Krishnapillai
1 7
,  reported as mild to moderate staining intensity in 
MDSCC.  
 
40% of cases showed intense staining for cyclin D1 in cases of 
VC and 30% of cases showed moderate and mild staining  (Figure 19)  
in contrast to Angadi and Krishnapillai
1 7
 where predominantly mild 
staining was observed.   
 
The difference between the mean scores of intensity of staining 
of cyclin D1 between the study groups was found to be statistically 
significant (p value = 0.012*)( Table 3)(Graph 1).  
 
The immunoreactivity for area of staining of cyclin D1 in the 
normal buccal mucosa showed less than 25% of positivity in the 
nucleus of  basal and parabasal cells.  The reason for the nuclear 
staining pattern in our study could be the due to the proliferative 
activity of the basal layer of cells as c yclin D1 regulates the transition 
of cells from G1 phase to S phase in cell  cycle
2 5
.
  
When considering the 
immunoreactivity for area of staining in WDSCC, 80% of samples  
showed 50- 100 % of  positivity (Figure 10 and 11). On analysing the 
immunoreactivity for area of staining of cyclin D1 in  MDSCC and VC  
60 % of cases showed less than 25 % of   positivity.   
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The difference between the mean scores of area of staining of 
cyclin D1 between the study groups was found to be statistically 
significant (p value = 0.001*)(Table 3) (Graph 1).  
 
In the present study, in WDSCC and MDSCC c yclin D1 was 
expressed in the outer layers of the epithelial tumour islands and cords 
since cyclin D1 is an activator of the cell proliferation cycle and 
peripheral cells  are those which are supposed to be the most 
proliferative and invasive ones in OSCC.  In VC, the expression of 
cyclin D1 was seen mostly in basal and parabasal layers and tends to 
diminish in the superﬁcial areas 1 7 .  
 
In the present study  maximum expression of  cyclin  D1  in OSCC 
(WDSCC and MDSCC) was observed which is similar to Swati  
Saawarn et al
1 6
,   Satya N. Das et al
1 8
,   Masayuki Shiraki et al  4 2 ,   
Sunit B. Patel  et al
5 2
,  and   Angadi and Krishnapillai
1 7
.  
 
The higher 
expression of cyclin  D1 observed in  OSCC might be explained by the 
fact that expression of this marker is  related to an intense proliferative 
activity and invasive capacity of the lesions
4 1 ,8 6
.  
 
In the present study,  the results in n ormal  mucosa showed that  
in 50% of cases MCM 2 was expressed with  moderate intensity of 
staining (Figure 35) .  
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In our study  100% of WDSCC (Figure 25),  80% of MDSCC and 
70% of VC (Figure 32) showed intense staining for MCM 2. These 
findings are in accordance with Kodani et al
5 4
,   Chatrath et al
8 8
,   
Heba N. Shalash
3 4
,  and Torres-Rendon et al
2 8
.  The difference 
between the mean scores of intensity of staining of MCM 2 between the 
study groups was found to be statistically significant (p value = 
0.015*) (Table 6) (Graph 2) .  
 
In the present study,  MCM-2 immunoexpression in epithelium of 
normal  mucosa was seen restricted to the basal and parabasal 
compartments with few reactive cells in the middle third and totally 
negative immunoexpression  in the upper third.  The immunoreactivity  
for area of staining of MCM 2 in normal mucosa was predominantly 
less than 50% of expression in basal and parabasal cells. This shows 
that  controlled cell division and proliferation ability occur mainly in 
basal and parabasal compartment while the superfi cial cells have lost  
their proliferative ability.  This result  was similar to that  of Chatrath 
et al
7 7
,  and  Chong-Jin  et al
7 8
.   In contrast, Torres-Rendon et al  
2 8
 
investigated MCM-2 expression in normal mucosa and found that  
MCM2 was mainly expressed at t he suprabasal compartment only.  
 
In the current study 70% of the  WDSCC showed more than 75% 
positivity of area of staining of MCM-2 (Figure 24) , with expression 
along the periphery of the invaded epithelial islands, and at the 
invasive fronts. On the other hand, the central  cores of the cell nests 
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mostly showed negative MCM-2 reaction. These observations are in 
accordance with Heba N. Shalash
3 4
,  Szelachowska et al
5 6
,  Scott et 
al
5 5
  and Gouvea et al
5 7
.  The increase in MCM-2 expression in the 
peripheral tumor cells and at  the invasive fronts  suggest  a high rate of 
cellular proliferation and  subsequent invasion into the surrounding 
structures
6 3
.   
 
In MDSCC, 50% of the samples showed more than  75% of 
positivity for area of  staining (Figure 27)   evident in the peripheral  
portions of the invading islands and showed  negative in the central  
core of keratin pearls. These findings are in accordance with Kodani et 
al
5 4
,   Chatrath et al
7 7
,   Heba N. Shalash
3 4
,  and   Torres-Rendon et 
al
2 8
.    
 
In our study 50% of VC cases showed more than 60% of 
positivity (Figure 30)  and 50% of  VC samples showed less than 50% 
positivity for  area of staining of MCM2. As mentioned by Gimenez 
Conti et al
7 9
,  VC is characterized by a diﬀerentiation of a high order 
and epithelium shows little mitotic activity , hence the cells taking up 
MCM 2 are lesser.  
 
The difference between the mean scores of area of staining of 
MCM 2 between the study groups was found to be statistically 
significant (p value = 0.003*) (Table 6) (Graph 2) .  
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In our study the mean LI of cyclin  D1 in normal mucosa was 
8.42 ±5.10. The   mean LI of cyclin D1 for OSCC  (WDSCC and 
MDSCC) was 20.086 ± 6.840 which is nearly similar to that of Uma 
Swaminathan et al
4 5  
 where the labelling index of cyclin D1 was 
18.88±13.70  in OSCC. 
 
The mean LI of cyclin D1 in VC in our study was 21.68 ±10.90 
but the results could not be compared directly due to lack of published 
reports.  
 
On Comparing the mean Labelling Index (LI) of Cyclin D1 
between the normal mucosa, OSCC and VC, statist ically significant 
value (p value= 0.001*) was obtained (Table 8).  
 
In the current study the mean value of LI of MCM 2   in normal 
mucosa was 18.33± 3.99 similar to observations by Kodani et al
5 4
 .  
 
The   mean LI of MCM 2  for  OSCC in the present study was 
43.599 ±15.33 which is similar to the value  of Kodani et al
5 4
 but in 
contrast  to the values reported by Niranjan et al
6 3
. ,  Torres–Rendon et 
al
2 8
. ,  and Razavi et al
3 6
.  
 
The   mean LI of MCM 2  for VC  in the present study was 40.67 
± 19.84. This finding is in contrast to the value reported by Niranjan 
et al
6 3  (89.22± 5.51).  
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On comparing the  mean LI of MCM 2 between the normal 
mucosa, OSCC and VC statistically significant value was obtained                   
( p value =0.002*) (Table 9).   
 
In our study, on comparison of mean LI of Cyclin D1 and MCM 
2 in NM, OSCC and VC statistically significant results (p<0.05) were  
obtained in all the study groups (Table 10) (Graph 4).  The  mean LI of 
MCM 2  in the study groups was found to be higher than the mean LI 
of Cyclin D1 in the present study. This could be because MCM -2 
proteins identify both cycling cells and non -cycling cells with 
proliferative potential
 
throughout the cell cycle and expressed in the 
cell  nucleus from early G1 phase.
3 6  
 
The present study is probably an early initiative to evaluate the 
immunohistochemical expression of cyclin D1 and  MCM 2 in OSCC 
and VC.  There was a substantial   increase in the immunoexpression 
and mean  LI  of Mcm-2 and cyclin D1 from Normal  mucosa to OSCC.  
 
 A similar progressive  increase in the  immunoexpression and 
mean  LI  of MCM 2 and cyclin D1 was observed from Normal  mucosa 
to verrucous carcinoma.  
 
 A thorough l iterature search was done to find out the expression 
of Cyclin D1 and MCM 2 in verruous carcinoma like lesions.  But only  
very few articles were obtained for reference. Hence the present study  
can have a place as one of the early studies attempted in expression of 
MCM2 and Cyclin D1 in VC.  
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SUMMARY AND CONCLUSION  
 
The aim of the study was to evaluate  the immunohistochemical 
expression of MCM2 and  Cyclin D1 in oral  squamous cell carcinoma 
and   oral  verrucous  carcinoma. A total  of 20 samples of OSCC, 10 
samples of VC & 10 samples of normal mucosa were included in the 
study and the t issue samples were taken from the archival retrieved 
from the formalin fixed, paraffin embedded tissues.  Immunoexpression 
of Cyclin D1 and MCM 2 were studied by qualitative and quantitative 
analysis. Qualitative analysis was done by evaluation of intensity of 
staining and area of staining. Quantitative analysis was done by 
calculating the percentage of positively stained cells and determining 
the Labelling Index (LI).  
 
From the present study done with Cyclin D1 and MCM 2, following 
conclusions were drawn: 
  On evaluating and comparing Cyclin D1 intensity and area of 
staining between the groups, statistically  significant values 
(p<0.05) were obtained.  
  On evaluating and comparing MCM 2 intensity an d area of  
staining between the groups, statistically  significant values 
(p<0.05) were obtained.  
  On Comparison of LI of Cyclin D1 between the groups, 
statistically significant value (p<0.05) was obtained.  
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  On Comparison of LI of   MCM 2 between the groups, 
statistically significant value (p<0.05) was obtained.  
  Comparison of LI of Cyclin D1 and MCM 2 in normal mucosa, 
oral  squamous cell carcinoma and verrucous carcinoma 
statistically significant results (p<0.05) were  obtained in all  the 
study groups.  
  On comparison of mean LI of MCM2 and Cyclin D1, the mean LI 
of MCM 2  was found to be significantly higher . This can be 
because  MCM 2 proteins are expressed in cell nucleus from 
early G1 phase. So   MCM2  can serve as a more potential  
biomarker for cell proliferation in OSCC and VC than when 
compared to Cyclin D1.  
  Further studies need to be pe rformed with larger sample size  to 
validate the present findings.  
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ANNEXURE II  
 
1.STUDY DATA SHOWING STAINING INTENSITY AND AREA 
OF STAINING OF CYCLIN D1 AND MCM2  
 
S.NO HP NO 
CYCLIN D1 MCM2 
Intensity Area Intensity Area 
NORMAL MUCOSA 
1 2890/16 2 1 3 2 
2 2902/16 2 1 2 1 
3 2926/16 1 1 2 1 
4 3473/17 1 1 1 1 
5 3768/17 3 3 3 2 
6 3492/17 2 2 3 2 
7 3476 1 1 2 2 
8 3217 1 1 1 1 
9 3106 1 2 2 2 
10 3406 1 2 2 3 
WELL DIFFERENTIATED SCC 
1 1367/16 2 3 3 2 
2 2128 A/16 3 4 3 4 
3 2832 B/16 3 3 3 4 
4 3000 C/16 3 4 3 4 
5 3138 A/16 3 4 3 4 
6 3782 A/17 3 4 3 4 
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7 3847 A/18 3 2 3 3 
8 3866 A/18 3 3 3 4 
9 3889 A2/18 2 2 3 3 
10 3931/18 3 3 3 4 
MODERATELY DIFFERENTIATED SCC 
1 1393/13 3 1 3 1 
2 1813 A 2 1 3 4 
3 2762 A/16 1 1 1 2 
4 2785/16 0 0 1 1 
5 3018/16 2 1 3 3 
6 3255/17 1 1 3 4 
7 3712/17 3 3 3 4 
8 3772 /17 3 2 3 4 
9 4016 A/18 3 4 3 4 
10 3841 A/18 3 1 3 2 
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 VERRUCOUS CARCINOMA 
S.NO HP NO CYCLIN D1 MCM2 
  Intensity Area Intensity Area 
1 84 B 2 2 3 4 
2 185 2 1 3 4 
3 442 1 1 3 2 
4 1273 B/13 3 3 3 3 
5 1554 B/14 3 2 1 2 
6 2036 /15 1 1 2 1 
7 2315 B 2 3 3 3 
8 3921 A2 3 1 3 1 
9 3923 A2 1 1 3 3 
10 3934 L 3 1 2 1 
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2.STUDY DATA SHOWING  LABELLING INDEX (LI) OF CYCLIN 
D1 AND MCM2 
 
S.NO HP NO 
CYCLIN D1 MCM2 
LI LI 
NORMAL MUCOSA 
1 2890/16 2.477% 21.497% 
2 2902/16 4.858% 17.391% 
3 2926/16 5.4498% 12.572% 
4 3473/17 6.425% 13.839% 
5 3768/17 13.138% 22.35% 
6 3492/17 17.028% 20.795% 
7 3476 4.287% 21.35% 
8 3217 5.102% 18.085% 
9 3106 15.19% 12.857% 
10 3406 10.132% 22.558% 
WELL DIFFERENTIATED SCC 
1 1367/16 17.468% 28.337% 
2 2128 A/16 27.505% 44.311% 
3 2832 B/16 13.537% 49.13% 
4 3000 C/16 24.457% 48.77% 
5 3138 A/16 18.518% 43.816% 
6 3782 A/17 26.213% 40.203% 
7 3847 A/18 11.787% 29.687% 
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8 3866 A/18 23.40% 69.655% 
9 3889 A2/18 22.357% 45.060% 
10 3931/18 25.215% 36.34% 
MODERATELY DIFFERENTIATED SCC 
1 1393/13 18.660% 73.113% 
2 1813 A 18.201% 54.883% 
3 2762 A/16 30% 32.648% 
4 2785/16 0 15.384% 
5 3018/16 24.449% 46.803% 
6 3255/17 15.990% 32.380% 
7 3712/17 26.039% 67.012% 
8 3772 /17 23.970% 39.583% 
9 4016 A/18 17.535% 53.936% 
10 3841 A/18 16.397% 20.930% 
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 VERRUCOUS CARCINOMA 
S.NO HP NO CYCLIN D1 MCM2 
  LI LI 
1 84 B 32.05% 37.5% 
2 185 19.315% 45.858% 
3 442 13.469% 64.427% 
4 1273 B/13 44.473% 60.199% 
5 1554 B/14 28.993% 23.577% 
6 2036 /15 14.223% 13.494% 
7 2315 B 25.31% 36.346% 
8 3921 A2 15.469% 57.110% 
9 3923 A2 14.188% 58.071% 
10 3934 L 9.318% 10.080% 
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